Advances in the preclinical testing of cancer therapeutic hypotheses (original) (raw)

• Hudson, T. J. et al. International network of cancer genome projects. Nature 464, 993–998 (2010).
  Article CAS PubMed Google Scholar
• Buchdunger, E. et al. Inhibition of the Abl protein-tyrosine kinase in vitro and in vivo by a 2-phenylaminopyrimidine derivative. Cancer Res. 56, 100–104 (1996).
  CAS PubMed Google Scholar
• Miller-Moslin, K. et al. 1-amino-4-benzylphthalazines as orally bioavailable smoothened antagonists with antitumor activity. J. Med. Chem. 52, 3954–3968 (2009).
  Article CAS PubMed Google Scholar
• Robarge, K. D. et al. GDC-0449 — a potent inhibitor of the hedgehog pathway. Bioorg. Med. Chem. Lett. 19, 5576–5581 (2009).
  Article CAS PubMed Google Scholar
• Barrie, S. E. et al. Pharmacology of novel steroidal inhibitors of cytochrome P45017α (17 alpha-hydroxylase/C17–20 lyase). J. Steroid Biochem. Mol. Biol. 50, 267–273 (1994).
  Article CAS PubMed Google Scholar
• Bhatnagar, A. S., Hausler, A., Schieweck, K., Lang, M. & Bowman, R. Highly selective inhibition of estrogen biosynthesis by CGS 20267, a new non-steroidal aromatase inhibitor. J. Steroid Biochem. Mol. Biol. 37, 1021–1027 (1990).
  Article CAS PubMed Google Scholar
• Plourde, P. V., Dyroff, M. & Dukes, M. Arimidex: a potent and selective fourth-generation aromatase inhibitor. Breast Cancer Res. Treat. 30, 103–111 (1994).
  Article CAS PubMed Google Scholar
• Sasai, K. et al. Shh pathway activity is down-regulated in cultured medulloblastoma cells: implications for preclinical studies. Cancer Res. 66, 4215–4222 (2006).
  Article CAS PubMed Google Scholar
• Kelly, P. N., Dakic, A., Adams, J. M., Nutt, S. L. & Strasser, A. Tumor growth need not be driven by rare cancer stem cells. Science 317, 337 (2007).
  Article CAS PubMed Google Scholar
• Quintana, E. et al. Efficient tumour formation by single human melanoma cells. Nature 456, 593–598 (2008).
  Article CAS PubMed PubMed Central Google Scholar
• Chabner, B. A. & Roberts, T. G. Jr. Chemotherapy and the war on cancer. Nature Rev. Cancer 5, 65–72 (2005).
  Article CAS Google Scholar
• DeVita, V. T. Jr & Chu, E. A history of cancer chemotherapy. Cancer Res. 68, 8643–8653 (2008).
  Article CAS PubMed Google Scholar
• Gilman, A. & Philips, F. S. The biological actions and therapeutic applications of the B-chloroethyl amines and sulfides. Science 103, 409–436 (1946).
  Article CAS PubMed Google Scholar
• Goodman, L. S. et al. Nitrogen mustard therapy; use of methyl-bis(beta-chloroethyl)amine hydrochloride and tris(beta-chloroethyl)amine hydrochloride for Hodgkin's disease, lymphosarcoma, leukemia and certain allied and miscellaneous disorders. JAMA 132, 126–132 (1946).
  Article CAS Google Scholar
• Rutman, R. J., Cantarow, A. & Paschkis, K. E. Studies in 2-acetylaminofluorene carcinogenesis. III. The utilization of uracil-2-C14 by preneoplastic rat liver and rat hepatoma. Cancer Res. 14, 119–123 (1954).
  CAS PubMed Google Scholar
• Heidelberger, C. et al. Fluorinated pyrimidines, a new class of tumour-inhibitory compounds. Nature 179, 663–666 (1957).
  Article CAS PubMed Google Scholar
• Fantini, A., Moser, L., Partridge, R. & Halliday, J. L. The effect of actinomycin D on several mouse tumors. Proc. Am. Assoc. Cancer Res. 2, 108 (1956).
  Google Scholar
• Farber, S. Carcinolytic action of antibiotics: puromycin and actinomycin D. Am. J. Pathol. 31, 582 (1955).
  Google Scholar
• Gregory, F. J., Hata, T., Pugh, L. H. & Thielen, R. The effect of actinomycin D on experimental ascitic tumors in the mouse. Cancer Res. 16, 985–987 (1956).
  CAS PubMed Google Scholar
• Johnson, I. S., Armstrong, J. G., Gorman, M. & Burnett, J. P. Jr. The vinca alkaloids: a new class of oncolytic agents. Cancer Res. 23, 1390–1427 (1963).
  CAS PubMed Google Scholar
• Pinkel, D. Actinomycin D in childhood cancer; a preliminary report. Pediatrics 23, 342–347 (1959).
  Article CAS PubMed Google Scholar
• Shoemaker, R. H. The NCI60 human tumour cell line anticancer drug screen. Nature Rev. Cancer 6, 813–823 (2006).
  Article CAS Google Scholar
• Holbeck, S. L., Collins, J. M. & Doroshow, J. H. Analysis of Food and Drug Administration-approved anticancer agents in the NCI60 panel of human tumor cell lines. Mol. Cancer Ther. 9, 1451–1460 (2010).
  Article CAS PubMed PubMed Central Google Scholar
• Bussey, K. J. et al. Integrating data on DNA copy number with gene expression levels and drug sensitivities in the NCI-60 cell line panel. Mol. Cancer Ther. 5, 853–867 (2006).
  Article CAS PubMed PubMed Central Google Scholar
• Garraway, L. A. et al. Integrative genomic analyses identify MITF as a lineage survival oncogene amplified in malignant melanoma. Nature 436, 117–122 (2005).
  Article CAS PubMed Google Scholar
• Ma, Y. et al. Predicting cancer drug response by proteomic profiling. Clin. Cancer Res. 12, 4583–4589 (2006).
  Article CAS PubMed Google Scholar
• Ring, B. Z., Chang, S., Ring, L. W., Seitz, R. S. & Ross, D. T. Gene expression patterns within cell lines are predictive of chemosensitivity. BMC Genomics 9, 74 (2008).
  Article PubMed PubMed Central CAS Google Scholar
• Ross, D. T. et al. Systematic variation in gene expression patterns in human cancer cell lines. Nature Genet. 24, 227–235 (2000).
  Article CAS PubMed Google Scholar
• Scherf, U. et al. A gene expression database for the molecular pharmacology of cancer. Nature Genet. 24, 236–244 (2000).
  Article CAS PubMed Google Scholar
• Solit, D. B. et al. BRAF mutation predicts sensitivity to MEK inhibition. Nature 439, 358–362 (2006).
  Article CAS PubMed Google Scholar
• Weinstein, J. N. et al. An information-intensive approach to the molecular pharmacology of cancer. Science 275, 343–349 (1997).
  Article CAS PubMed Google Scholar
• Bai, R. L. et al. Halichondrin B and homohalichondrin B, marine natural products binding in the vinca domain of tubulin. Discovery of tubulin-based mechanism of action by analysis of differential cytotoxicity data. J. Biol. Chem. 266, 15882–15889 (1991).
  Article CAS PubMed Google Scholar
• Leteurtre, F., Kohlhagen, G., Paull, K. D. & Pommier, Y. Topoisomerase II inhibition and cytotoxicity of the anthrapyrazoles DuP 937 and DuP 941 (Losoxantrone) in the National Cancer Institute preclinical antitumor drug discovery screen. J. Natl Cancer Inst. 86, 1239–1244 (1994).
  Article CAS PubMed Google Scholar
• Solary, E. et al. Dual inhibition of topoisomerase II and tubulin polymerization by azatoxin, a novel cytotoxic agent. Biochem. Pharmacol. 45, 2449–2456 (1993).
  Article CAS PubMed Google Scholar
• Adams, J. Development of the proteasome inhibitor PS-341. Oncologist 7, 9–16 (2002).
  Article CAS PubMed Google Scholar
• Weir, B. A. et al. Characterizing the cancer genome in lung adenocarcinoma. Nature 450, 893–898 (2007).
  Article CAS PubMed PubMed Central Google Scholar
• Zhao, X. et al. Homozygous deletions and chromosome amplifications in human lung carcinomas revealed by single nucleotide polymorphism array analysis. Cancer Res. 65, 5561–5570 (2005).
  Article CAS PubMed Google Scholar
• Ding, L. et al. Somatic mutations affect key pathways in lung adenocarcinoma. Nature 455, 1069–1075 (2008).
  Article CAS PubMed PubMed Central Google Scholar
• Rodig, S. J. et al. Unique clinicopathologic features characterize ALK-rearranged lung adenocarcinoma in the western population. Clin. Cancer Res. 15, 5216–5223 (2009).
  Article CAS PubMed PubMed Central Google Scholar
• Soda, M. et al. Identification of the transforming EML4_–_ALK fusion gene in non-small-cell lung cancer. Nature 448, 561–566 (2007).
  Article CAS PubMed Google Scholar
• McDermott, U. et al. Genomic alterations of anaplastic lymphoma kinase may sensitize tumors to anaplastic lymphoma kinase inhibitors. Cancer Res. 68, 3389–3395 (2008).
  Article CAS PubMed Google Scholar
• McDermott, U. et al. Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profiling. Proc. Natl Acad. Sci. USA 104, 19936–19941 (2007).
  Article CAS PubMed PubMed Central Google Scholar
• Kwak, E. L. et al. Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. N. Engl. J. Med. 363, 1693–1703 (2010).
  Article CAS PubMed PubMed Central Google Scholar
• Shaw, A. T. et al. Clinical features and outcome of patients with non-small-cell lung cancer who harbor EML4–ALK. J. Clin. Oncol. 27, 4247–4253 (2009).
  Article CAS PubMed PubMed Central Google Scholar
• Koivunen, J. P. et al. EML4_–_ALK fusion gene and efficacy of an ALK kinase inhibitor in lung cancer. Clin. Cancer Res. 14, 4275–4283 (2008).
  Article CAS PubMed PubMed Central Google Scholar
• Soda, M. et al. A mouse model for EML4–ALK-positive lung cancer. Proc. Natl Acad. Sci. USA 105, 19893–19897 (2008).
  Article CAS PubMed PubMed Central Google Scholar
• Dry, J. R. et al. Transcriptional pathway signatures predict MEK addiction and response to selumetinib (AZD6244). Cancer Res. 70, 2264–2273 (2010).
  Article CAS PubMed PubMed Central Google Scholar
• Greshock, J. et al. Molecular target class is predictive of in vitro response profile. Cancer Res. 70, 3677–3686 (2010).
  Article CAS PubMed Google Scholar
• Lin, W. M. et al. Modeling genomic diversity and tumor dependency in malignant melanoma. Cancer Res. 68, 664–673 (2008).
  Article CAS PubMed Google Scholar
• Sos, M. L. et al. Predicting drug susceptibility of non-small cell lung cancers based on genetic lesions. J. Clin. Invest. 119, 1727–1740 (2009).
  Article CAS PubMed PubMed Central Google Scholar
• Davies, B. R. et al. AZD6244 (ARRY-142886), a potent inhibitor of mitogen-activated protein kinase/extracellular signal-regulated kinase kinase 1/2 kinases: mechanism of action in vivo, pharmacokinetic/pharmacodynamic relationship, and potential for combination in preclinical models. Mol. Cancer Ther. 6, 2209–2219 (2007).
  Article CAS PubMed Google Scholar
• Yeh, J. J. et al. KRAS/BRAF mutation status and ERK1/2 activation as biomarkers for MEK1/2 inhibitor therapy in colorectal cancer. Mol. Cancer Ther. 8, 834–843 (2009).
  Article CAS PubMed PubMed Central Google Scholar
• Engelman, J. A. et al. Effective use of PI3K and MEK inhibitors to treat mutant Kras G12D and PIK3CA H1047R murine lung cancers. Nature Med. 14, 1351–1356 (2008).
  Article CAS PubMed Google Scholar
• Wee, S. et al. PI3K pathway activation mediates resistance to MEK inhibitors in KRAS mutant cancers. Cancer Res. 69, 4286–4293 (2009).
  Article CAS PubMed Google Scholar
• Borisy, A. A. et al. Systematic discovery of multicomponent therapeutics. Proc. Natl Acad. Sci. USA 100, 7977–7982 (2003).
  Article CAS PubMed PubMed Central Google Scholar
• Sos, M. L. et al. Identifying genotype-dependent efficacy of single and combined PI3K- and MAPK-pathway inhibition in cancer. Proc. Natl Acad. Sci. USA 106, 18351–18356 (2009).
  Article CAS PubMed PubMed Central Google Scholar
• Engelman, J. A. & Janne, P. A. Mechanisms of acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer. Clin. Cancer Res. 14, 2895–2899 (2008).
  Article PubMed Google Scholar
• Kobayashi, S. et al. EGFR mutation and resistance of non-small-cell lung cancer to gefitinib. N. Engl. J. Med. 352, 786–792 (2005).
  Article CAS PubMed Google Scholar
• Pao, W. et al. Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain. PLoS Med. 2, e73 (2005).
  Article PubMed PubMed Central CAS Google Scholar
• Engelman, J. A. et al. MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling. Science 316, 1039–1043 (2007).
  Article CAS PubMed Google Scholar
• Turke, A. B. et al. Preexistence and clonal selection of MET amplification in EGFR mutant NSCLC. Cancer Cell 17, 77–88 (2010).
  Article CAS PubMed PubMed Central Google Scholar
• Beroukhim, R. et al. Assessing the significance of chromosomal aberrations in cancer: methodology and application to glioma. Proc. Natl Acad. Sci. USA 104, 20007–20012 (2007).
  Article CAS PubMed PubMed Central Google Scholar
• Li, A. et al. Genomic changes and gene expression profiles reveal that established glioma cell lines are poorly representative of primary human gliomas. Mol. Cancer Res. 6, 21–30 (2008).
  Article CAS PubMed Google Scholar
• Wakimoto, H. et al. Human glioblastoma-derived cancer stem cells: establishment of invasive glioma models and treatment with oncolytic herpes simplex virus vectors. Cancer Res. 69, 3472–3481 (2009).
  Article CAS PubMed PubMed Central Google Scholar
• Ellis, W. J. et al. Characterization of a novel androgen-sensitive, prostate-specific antigen-producing prostatic carcinoma xenograft: LuCaP 23. Clin. Cancer Res. 2, 1039–1048 (1996).
  CAS PubMed Google Scholar
• Klein, K. A. et al. Progression of metastatic human prostate cancer to androgen independence in immunodeficient SCID mice. Nature Med. 3, 402–408 (1997).
  Article CAS PubMed Google Scholar
• Korenchuk, S. et al. VCaP, a cell-based model system of human prostate cancer. In Vivo 15, 163–168 (2001).
  CAS PubMed Google Scholar
• Lee, Y. G. et al. Establishment and characterization of a new human prostatic cancer cell line: DuCaP. In Vivo 15, 157–162 (2001).
  CAS PubMed Google Scholar
• Wainstein, M. A. et al. CWR22: androgen-dependent xenograft model derived from a primary human prostatic carcinoma. Cancer Res. 54, 6049–6052 (1994).
  CAS PubMed Google Scholar
• Rong, S. et al. Tumorigenicity of the met proto-oncogene and the gene for hepatocyte growth factor. Mol. Cell Biol. 12, 5152–5158 (1992).
  CAS PubMed PubMed Central Google Scholar
• Tian, H. et al. Hedgehog signaling is restricted to the stromal compartment during pancreatic carcinogenesis. Proc. Natl Acad. Sci. USA 106, 4254–4259 (2009).
  Article CAS PubMed PubMed Central Google Scholar
• Yauch, R. L. et al. A paracrine requirement for hedgehog signalling in cancer. Nature 455, 406–410 (2008).
  Article CAS PubMed Google Scholar
• Sharpless, N. E. & Depinho, R. A. The mighty mouse: genetically engineered mouse models in cancer drug development. Nature Rev. Drug Discov. 5, 741–754 (2006).
  Article CAS Google Scholar
• Olive, K. P. et al. Inhibition of Hedgehog signaling enhances delivery of chemotherapy in a mouse model of pancreatic cancer. Science 324, 1457–1461 (2009).
  Article CAS PubMed PubMed Central Google Scholar
• Buonamici, S. et al. Interfering with resistance to smoothened antagonists by inhibition of the PI3K pathway in medulloblastoma. Sci. Transl. Med. 2, 51ra70 (2010).
  Article PubMed PubMed Central CAS Google Scholar
• Zhou, Y. et al. Chimeric mouse tumor models reveal differences in pathway activation between ERBB family- and KRAS-dependent lung adenocarcinomas. Nature Biotech. 28, 71–78 (2010).
  Article CAS Google Scholar
• Kinzler, K. W. & Vogelstein, B. Landscaping the cancer terrain. Science 280, 1036–1037 (1998).
  Article CAS PubMed Google Scholar
• Kaiser, J. Cancer research. Looking for a target on every tumor. Science 326, 218–220 (2009).
  Article CAS PubMed Google Scholar
• Druker, B. J. et al. Efficacy and safety of a specific inhibitor of the BCR–ABL tyrosine kinase in chronic myeloid leukemia. N. Engl. J. Med. 344, 1031–1037 (2001).
  Article CAS PubMed Google Scholar
• Bollag, G. et al. Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma. Nature 467, 596–599 (2010).
  Article CAS PubMed PubMed Central Google Scholar
• Vogel, C. L. et al. Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer. J. Clin. Oncol. 20, 719–726 (2002).
  Article CAS PubMed Google Scholar
• Fremin, C. & Meloche, S. From basic research to clinical development of MEK1/2 inhibitors for cancer therapy. J. Hematol. Oncol. 3, 8 (2010).
  Article PubMed PubMed Central CAS Google Scholar
• Baum, M. et al. Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomised trial. Lancet 359, 2131–2139 (2002).
  Article CAS PubMed Google Scholar
• Danila, D. C. et al. Phase II multicenter study of abiraterone acetate plus prednisone therapy in patients with docetaxel-treated castration-resistant prostate cancer. J. Clin. Oncol. 28, 1496–1501 (2010).
  Article CAS PubMed PubMed Central Google Scholar
• Reid, A. H. et al. Significant and sustained antitumor activity in post-docetaxel, castration-resistant prostate cancer with the CYP17 inhibitor abiraterone acetate. J. Clin. Oncol. 28, 1489–1495 (2010).
  Article CAS PubMed PubMed Central Google Scholar
• Ryan, C. J. et al. Phase I clinical trial of the CYP17 inhibitor abiraterone acetate demonstrating clinical activity in patients with castration-resistant prostate cancer who received prior ketoconazole therapy. J. Clin. Oncol. 28, 1481–1488 (2010).
  Article CAS PubMed PubMed Central Google Scholar
• Drew, Y. & Plummer, R. PARP inhibitors in cancer therapy: two modes of attack on the cancer cell widening the clinical applications. Drug Resist. Updat. 12, 153–156 (2009).
  Article CAS PubMed Google Scholar